Postoperative adjuvant donafenib combined with PD-1 checkpoint inhibitor for patients at high risk of recurrence.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-05-28
DOI
https://doi.org/10.1200/jco.2025.43.16_suppl.e16276
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Postoperative adjuvant donafenib combined with PD-1 checkpoint inhibitor for patients at high risk of recurrence.

Wei Gong
Journal of Clinical Oncology
Colorectal Cancer Treatments and Studies
article

Postoperative adjuvant donafenib combined with PD-1 checkpoint inhibitor for patients at high risk of recurrence.

Wei Gong
article en

Abstract

No abstract available for this paper.
Journal of Clinical OncologyVol. 43(16_suppl)
Shandong Provincial Hospital (CN), Shandong First Medical University (CN)
Good health and well-being
Openalex Percentile: Top 82%
Colorectal Cancer Treatments and Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Postoperative adjuvant donafenib combined with PD-1 checkpoint inhibitor for patients at high risk of recurrence. — Wei Gong · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS